Studies have shown that azacitidine inhibits the activation of STAT3 by restoring SHP1 and down-regulating DNMT1, suggesting that azacitidine as a potential targeted therapy for LGLL (15). This evidence concerns the gene DNMT1 and T-cell large granular lymphocyte leukemia.